Kestra Medical Technologies
- Market cap
- 1.58B
- P/E (TTM)i
- -10.47
- P/Bi
- 7.10
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 72%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Kestra Medical Technologies (KMTS) | 1.58B | -10.47 | 7.10 | 0.00% |
| Intuitive Surgical (ISRG) | 146.44B | 47.54 | 8.06 | 0.00% |
| Becton Dickinson & Co (BDX) | 49.07B | 54.43 | 2.01 | 2.33% |
| ResMed (RMD) | 31.78B | 21.67 | 4.83 | 1.06% |
| Medline (MDLN) | 31.10B | 67.27 | 2.69 | 0.00% |
| Alcon (ALC) | 30.45B | 48.09 | 1.41 | 0.56% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 44.6% below Morningstar's fair value estimate.
Fair value
Kestra Medical Technologies Ltd receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 29% discount to our quantitative fair value estimate of $38.31 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 0.9, which ranks in the bottom 30% globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.
Alternatively, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 6.9%, a core component of profitability, lies in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.